This site is intended for Healthcare professionals only.

2017 update on Diabetic Retinopathy Preferred Practice Pattern by AAO

2017 update on Diabetic Retinopathy Preferred Practice Pattern by AAO

The American Academy of Ophthalmology (AAO) has released a 2017 update on its Preferred Practice Pattern guidelines on Diabetic Retinopathy in January 2016.   The prevalence of diabetes, both worldwide and in the United States, is increasing; as such, the prevalence of diabetic retinopathy and vision-threatening diabetic retinopathy (VTDR) is also expected to increase dramatically.Currently, only about 60% of people with diabetes have yearly screenings for diabetic retinopathy.

Major Recommendations:

  1. People with Type 1 diabetes should have annual screenings for diabetic retinopathy beginning 5 years after the onset of their disease, whereas those with Type 2 diabetes should have a prompt examination at the time of diagnosis and at least yearly examinations thereafter.
  2. Maintaining near-normal glucose levels and near-normal blood pressure lowers the risk of retinopathy developing and/or progressing, so patients should be informed of the importance of maintaining good glycosylated hemoglobin levels, serum lipids, and blood pressure.
  3. Patients with diabetes may use aspirin for other medical indications without an adverse effect on their risk of diabetic retinopathy.
  4. Women who develop gestational diabetes do not require an eye examination during pregnancy and do not appear to be at increased risk of developing diabetic retinopathy during pregnancy. However, patients with diabetes who become pregnant should be examined early in the course of the pregnancy.
  5. Referral to an ophthalmologist is required when there is any nonproliferative diabetic retinopathy, proliferative retinopathy, or macular edema.
  6. Ophthalmologists should communicate both ophthalmologic findings and level of retinopathy to the primary care physician. They should emphasize to the patient the need to adhere to the primary care physician’s guidance to optimize metabolic control.
  7. Intravitreal injections of anti-vascular endothelial growth factor (VEGF) agents have been shown to be an effective treatment for center-involving diabetic macular edema and also as an alternative therapy for proliferative diabetic retinopathy.
  8. At this time, laser photocoagulation remains the preferred treatment for non-center-involving diabetic macular edema.

For further reference log on to :

The following two tabs change content below.
Dr. Kamal Kant Kohli

Dr. Kamal Kant Kohli

A Medical practitioner with a flair for writing medical articles, Dr Kamal Kant Kohli joined Medical Dialogues as an Editor-in-Chief for the Speciality Medical Dialogues. Before Joining Medical Dialogues, he has served as the Hony. Secretary of the Delhi Medical Association as well as the chairman of Anti-Quackery Committee in Delhi and worked with other Medical Councils of India. Email: Contact no. 011-43720751
Source: American Academy of Ophthalmology

Share your Opinion Disclaimer

Sort by: Newest | Oldest | Most Voted